APVO Quote, Financials, Valuation and Earnings

Eyenovia has a net margin of -- compared to Aptevo Therapeutics's net margin of -485406.34%. Aptevo Therapeutics's return on equity of -- beat Eyenovia's return on equity of -676.86%.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 381.65%. On the other hand Eyenovia has an analysts' consensus of -- which suggests that it could grow by 3918.37%. Given that Eyenovia has higher upside potential than Aptevo Therapeutics, analysts believe Eyenovia is more attractive than Aptevo Therapeutics.

Aptevo Therapeutics has a beta of 5.014, which suggesting that the stock is 401.43% more volatile than S&P 500. In comparison Eyenovia has a beta of 1.434, suggesting its more volatile than the S&P 500 by 43.383%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eyenovia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Eyenovia pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Eyenovia quarterly revenues of $1.6K. Aptevo Therapeutics's net income of -$5.1M is higher than Eyenovia's net income of -$7.9M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Eyenovia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 148.94x for Eyenovia. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to Aptevo Therapeutics's net margin of 11.99%. Aptevo Therapeutics's return on equity of -- beat Johnson & Johnson's return on equity of 20.88%.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 381.65%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 20.63%. Given that Aptevo Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Aptevo Therapeutics is more attractive than Johnson & Johnson.

Aptevo Therapeutics has a beta of 5.014, which suggesting that the stock is 401.43% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.36% to investors and pays a quarterly dividend of $1.24 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Aptevo Therapeutics's net income of -$5.1M is lower than Johnson & Johnson's net income of $2.7B. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 4.00x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics has a net margin of -- compared to Aptevo Therapeutics's net margin of -13648.45%. Aptevo Therapeutics's return on equity of -- beat Keros Therapeutics's return on equity of -44.6%.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 381.65%. On the other hand Keros Therapeutics has an analysts' consensus of -- which suggests that it could grow by 186.13%. Given that Aptevo Therapeutics has higher upside potential than Keros Therapeutics, analysts believe Aptevo Therapeutics is more attractive than Keros Therapeutics.

Aptevo Therapeutics has a beta of 5.014, which suggesting that the stock is 401.43% more volatile than S&P 500. In comparison Keros Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Keros Therapeutics pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Keros Therapeutics quarterly revenues of $388K. Aptevo Therapeutics's net income of -$5.1M is higher than Keros Therapeutics's net income of -$53M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Keros Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus 912.41x for Keros Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -- compared to Aptevo Therapeutics's net margin of --. Aptevo Therapeutics's return on equity of -- beat Trevi Therapeutics's return on equity of --.

Aptevo Therapeutics has a consensus price target of $21.00, signalling upside risk potential of 381.65%. On the other hand Trevi Therapeutics has an analysts' consensus of $9.43 which suggests that it could grow by 142.28%. Given that Aptevo Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Aptevo Therapeutics is more attractive than Trevi Therapeutics.

Aptevo Therapeutics has a beta of 5.014, which suggesting that the stock is 401.43% more volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.172%.

Aptevo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Aptevo Therapeutics quarterly revenues are --, which are smaller than Trevi Therapeutics quarterly revenues of --. Aptevo Therapeutics's net income of -$5.1M is higher than Trevi Therapeutics's net income of -$13.2M. Notably, Aptevo Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics is 0.03x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.